Mesoblast CEO Silviu Itescu details equity holdings
Mesoblast Ltd CEO and Managing Director Silviu Itescu has filed an initial Form 3 detailing his beneficial ownership in the company.
Rhea-AI Filing Summary
Mesoblast Ltd CEO and Managing Director Silviu Itescu has filed an initial Form 3 detailing his beneficial ownership in the company. The filing lists substantial direct holdings of Mesoblast ordinary shares along with additional shares held indirectly through entities associated with him.
It also discloses multiple option awards over Mesoblast ordinary shares at exercise prices ranging from $0.01 to $3.39 per share, with expirations extending out to 2031. These options provide the right to acquire additional ordinary shares if exercised before their respective expiration dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
31 transactions reported
Mixed
31 txns
Insider
Itescu Silviu
Role
CEO and Managing Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 10,572,559 contracts (Direct);
Ordinary Shares — 67,756,838 shares (Direct);
Ordinary Shares — 8,821,137 shares (Indirect, Owned by Josaka Investments Pty Ltd, the trustee of Dr. Itescu's self-managed superannuation fund);
Ordinary Shares — 2,380,953 shares (Indirect, Owned by Tamit Nominees Pty Ltd, an Australian corporation owned by Dr. Itescu)
Key Figures
Direct ordinary shares: 67,756,838 shares
Indirect shares via Josaka Investments: 8,821,137 shares
Indirect shares via Tamit Nominees: 2,380,953 shares
+5 more
8 metrics
Direct ordinary shares
67,756,838 shares
Direct Mesoblast ordinary shares held as of the Form 3
Indirect shares via Josaka Investments
8,821,137 shares
Ordinary shares owned by Josaka Investments Pty Ltd
Indirect shares via Tamit Nominees
2,380,953 shares
Ordinary shares owned by Tamit Nominees Pty Ltd
Option block at $1.45
628,445 shares
Option over ordinary shares at $1.45, expiring July 19, 2026
Option block at $3.39
480,000 shares
Option over ordinary shares at $3.39, expiring July 15, 2027
Low‑priced options at $0.01
266,640 shares
One option grant over ordinary shares at $0.01, expiring September 9, 2031
Large option at $0.97
1,191,384 shares
Option over ordinary shares at $0.97, expiring August 26, 2031
Option at $1.01
930,000 shares
Option over ordinary shares at $1.01, expiring October 16, 2029
Key Terms
Option (right to buy), Ordinary Shares, self-managed superannuation fund, indirect ownership, +1 more
5 terms
Option (right to buy) financial
"security_title: "Option (right to buy)" over Mesoblast ordinary shares"
self-managed superannuation fund financial
"Owned by Josaka Investments Pty Ltd, the trustee of Dr. Itescu's self-managed superannuation fund"
indirect ownership financial
"ownership_type: "indirect" for shares held through Josaka Investments and Tamit Nominees"
exercise price financial
"conversion_or_exercise_price values such as "0.0100" and "3.3900" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Mesoblast (MESO) CEO Silviu Itescu’s Form 3 filing show?
The Form 3 shows Silviu Itescu’s initial beneficial ownership in Mesoblast, including direct ordinary shares, indirect holdings through related entities, and multiple option grants. It establishes his baseline equity position as CEO and Managing Director at the time of reporting.
What stock options are reported for Mesoblast (MESO) CEO Silviu Itescu?
The filing lists several option positions over Mesoblast ordinary shares with exercise prices such as $1.45, $1.75, $3.39, $0.97, $0.35, $0.36, and $0.01 per share. These options have various expiration dates, some extending to 2031.
What is the largest individual Mesoblast (MESO) option block held by Silviu Itescu?
One of the largest individual option positions reported covers 1,191,384 underlying ordinary shares at an exercise price of $0.97 per share, expiring on August 26, 2031. This option represents a significant potential future share acquisition if exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
